Approved mTOR inhibitors scored even lower for both everolimus (CNS-MPO: 1.25) and temsirolimus (CNS-MPO: 1.00) suggesting that currently approved drugs have more active mechanisms of brain uptake, or are unlikely to be effective for brain tumors. This evidence concerns the gene MPO and brain neoplasm.